DUBLIN – Northern Biologics Inc. is merging with Spanish firm Mosaic Biomedicals SL and at the same time has lined up Celgene Corp. with an option to take forward Mosaic's key asset, MSC-1, a first-in-class antibody that targets leukemia inhibitory factor (LIF).